GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Net Interest Income (for Banks)

Boundless Bio (Boundless Bio) Net Interest Income (for Banks)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Boundless Bio (Boundless Bio) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.